Immutep Faces Class Action Lawsuit, Stock Plummets 83%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IMMP?
Source: Globenewswire
- Class Action Initiated: Immutep Limited is facing a class action lawsuit for disseminating false information between March 24, 2025, and March 12, 2026, under case number 1:26-cv-03705, indicating significant risks in its clinical trials that could lead to investor losses.
- Stock Price Crash: Following the announcement on March 13, 2026, that the TACTI-004 Phase III clinical trial was discontinued due to futility, Immutep's ADR price plummeted from $2.76 to $0.48, representing an approximately 83% decline, severely impacting investor confidence.
- Investor Compensation Commitment: Levi & Korsinsky LLP is committed to securing full compensation for investors who suffered losses due to corporate misrepresentations, urging IMMP shareholders to step forward by the July 6, 2026 deadline to seek justice.
- Law Firm's Track Record: Over the past 20 years, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has extensive expertise in complex securities litigation, being ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its capability in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.461
Low
12.00
Averages
12.00
High
12.00
Current: 0.461
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep Faces Class Action Lawsuit, Stock Plummets 83%
- Class Action Initiated: Immutep Limited is facing a class action lawsuit for disseminating false information between March 24, 2025, and March 12, 2026, under case number 1:26-cv-03705, indicating significant risks in its clinical trials that could lead to investor losses.
- Stock Price Crash: Following the announcement on March 13, 2026, that the TACTI-004 Phase III clinical trial was discontinued due to futility, Immutep's ADR price plummeted from $2.76 to $0.48, representing an approximately 83% decline, severely impacting investor confidence.
- Investor Compensation Commitment: Levi & Korsinsky LLP is committed to securing full compensation for investors who suffered losses due to corporate misrepresentations, urging IMMP shareholders to step forward by the July 6, 2026 deadline to seek justice.
- Law Firm's Track Record: Over the past 20 years, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has extensive expertise in complex securities litigation, being ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its capability in handling such cases.
See More
Immutep Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for possibly issuing materially misleading business information, highlighting significant deficiencies in the company's information transparency.
- Stock Price Plunge Impact: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, indicating that the legal risks faced by the company may further exacerbate its financial pressures.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism about the company's future.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, suggesting the company may face substantial legal liabilities.
- Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in the securities litigation field.
See More
Rosen Law Firm Investigates Securities Claims for Immutep Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for possibly issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuation of the TACTI-004 Phase III study, reflecting market pessimism about the company's future.
- Class Action Preparation: The Rosen Law Firm is preparing a class action for affected investors, allowing them to seek compensation without any out-of-pocket costs, demonstrating the firm's commitment to protecting investor rights.
- Firm's Strength: Known for its successful track record in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, highlighting its leadership and expertise in the industry.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of misleading business information, highlighting serious concerns about the company's transparency and investor trust.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing investors to seek compensation without any out-of-pocket costs, which may attract more affected investors and enhance the lawsuit's potential impact.
- Firm's Track Record: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Rosen Law Firm Investigates Securities Claims Against Immutep Ltd.
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for allegedly issuing materially misleading business information, indicating possible legal liabilities for the company.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for investors who purchased Immutep securities, with no out-of-pocket fees required, which may encourage more affected investors to participate.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and extensive experience in this field.
See More
Immutep Faces Class Action Lawsuit, Stock Plummets 83%
- Class Action Initiated: Immutep Limited is facing a class action lawsuit for disseminating false information between March 24, 2025, and March 12, 2026, under case number 1:26-cv-03705, indicating significant risks in its clinical trials that could lead to investor losses.
- Stock Price Crash: Following the announcement on March 13, 2026, that the TACTI-004 Phase III clinical trial was discontinued due to futility, Immutep's ADR price plummeted from $2.76 to $0.48, representing an approximately 83% decline, severely impacting investor confidence.
- Investor Compensation Commitment: Levi & Korsinsky LLP is committed to securing full compensation for investors who suffered losses due to corporate misrepresentations, urging IMMP shareholders to step forward by the July 6, 2026 deadline to seek justice.
- Law Firm's Track Record: Over the past 20 years, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and has extensive expertise in complex securities litigation, being ranked among the top securities litigation firms in the U.S. for seven consecutive years, showcasing its capability in handling such cases.
See More
Immutep Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) for possibly issuing materially misleading business information, highlighting significant deficiencies in the company's information transparency.
- Stock Price Plunge Impact: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism regarding the company's future prospects.
- Class Action Preparation: Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, indicating that the legal risks faced by the company may further exacerbate its financial pressures.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting extreme market pessimism about the company's future.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Immutep, allowing investors to seek compensation without any out-of-pocket fees, suggesting the company may face substantial legal liabilities.
- Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in the securities litigation field.
See More
Rosen Law Firm Investigates Securities Claims for Immutep Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for possibly issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuation of the TACTI-004 Phase III study, reflecting market pessimism about the company's future.
- Class Action Preparation: The Rosen Law Firm is preparing a class action for affected investors, allowing them to seek compensation without any out-of-pocket costs, demonstrating the firm's commitment to protecting investor rights.
- Firm's Strength: Known for its successful track record in securities class actions, Rosen Law Firm recovered over $438 million for investors in 2019 alone, highlighting its leadership and expertise in the industry.
See More
Rosen Law Firm Investigates Immutep Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ: IMMP) due to allegations of misleading business information, highlighting serious concerns about the company's transparency and investor trust.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing investors to seek compensation without any out-of-pocket costs, which may attract more affected investors and enhance the lawsuit's potential impact.
- Firm's Track Record: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Rosen Law Firm Investigates Securities Claims Against Immutep Ltd.
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. (NASDAQ:IMMP) for allegedly issuing materially misleading business information, indicating possible legal liabilities for the company.
- Stock Price Plunge: On March 13, 2026, Immutep's ADR price fell by $2.28, or 82.6%, to close at $0.48 after the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, severely impacting investor confidence.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for investors who purchased Immutep securities, with no out-of-pocket fees required, which may encourage more affected investors to participate.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and extensive experience in this field.
See More
